Introducing our White Paper: "Bioactive Glass for Lumbar and Cervical Spine Fusion: A Retrospective Case Series." Explore the alternative of NovaBone Collagen Bioglass Bone Graft, a unique biomaterial with osteoconductive properties, through a retrospective analysis of 251 patients.
Lumbar and cervical fusion remain the gold standard to treat various spinal disorders, such as degenerative disc disease and spinal stenosis. Traditional bone grafts have shown good clinical success but have limitations. Bioactive glass is a unique class of biomaterials with osteoconductive properties that make it a compelling alternative to traditional bone grafts and/or biologics. Here, we review a large retrospective case series of patients treated with NovaBone Collagen Bioglass Bone Graft (NovaBone) in both cervical and lumbar fusion surgery.
About NovaBone
NovaBone, a Halma company, is privately held and based in Florida since 2002. NovaBone developed the first bioactive synthetic bone graft offered to the orthopedic community and has long been at the forefront of bioactive glass bone graft devices. It has developed numerous formulations and delivery systems of its patented, bioactive technology platform that results in accelerated bone growth. In total, their exclusively formulated bone graft substitute has been used for the repair of osseous defects throughout the skeletal system for over a decade and used in over a million clinical applications with unparalleled success validating the safety and efficacy of NovaBone's technology.
